We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BD (BDX) to Boost Lab Efficacy With BD Kiestra UCA's U.S. Launch
Read MoreHide Full Article
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, recently announced the U.S. launch of a Urine Culture Application (“UCA”) for use with the BD Kiestra lab automation incubation and imaging system. The application, which has been designed utilizing AI and leveraging the quality of BD BBL plated media, is expected to change the way microbiology labs approach urine culture analysis.
For investors’ note, the latest urine culture app can be used with both standalone BD Kiestra ReadA systems as well as track-based BD Kiestra laboratory automation solutions.
With the latest launch, BD aims to solidify its foothold in the global Integrated Diagnostic Solutions business. Notably, the Integrated Diagnostic Solutions is a part of the broader BD Life Sciences segment.
Significance of the Launch
It is noteworthy to mention that urine cultures consist of a significant part of the daily workload in many labs. However, the majority of those samples do not require any additional work-up.
The UCA is expected to utilize digital imaging and software algorithms to determine the amount of growth on a urine culture plate from clean-caught and catheterized samples. The BD Kiestra system's intelligent incubation and imaging device uses high-throughput robotics to decide which plates automatically go into a queue for clinician analysis and discards the rest.
Per management, the use of the UCA to automatically organize specimens into meaningful worklists is expected to help laboratories work more efficiently and better prioritize their efforts to focus on the most critical and complex specimens. Further, as reading plates is one of the laboratory tasks requiring the maximum skill, and given the dearth of skilled technicians in the workforce along with the pandemic-led challenges to the resources, lab efficiency is of utmost importance.
Industry Prospects
Per a report by Fior Markets, the global urinalysis market is expected to grow from $3.37 billion in 2019 to $6.32 billion by 2027 at a CAGR of approximately 8.1%. Factors like increasing cases of kidney-related diseases and rapid technological developments are likely to drive the market.
Given the market potential, the latest launch is expected to significantly strengthen BD’s global business.
Recent Developments
Of late, BD has witnessed a few notable developments across its businesses.
The company, this month, launched the BD Surgiphor Sterile Wound Irrigation System. It is the first and only ready-to-use aqueous povidone-iodine (PVP-I) irrigation solution currently available in the market which mechanically loosens and removes wound debris.
Also in May, BD announced that the industry's first self-collection claim for HPV screening has received the CE mark. The same month, the company reported solid fiscal 2021 second-quarter results with solid contribution by its COVID-19 diagnostic revenues.
In April, the company, along with CerTest Biotec, announced that the VIASURE SARS-CoV-2 (N1 + N2) Real Time PCR (polymerase chain reaction) Detection Kit for the BD MAX Molecular Diagnostic System can be run on saliva specimens.
Price Performance
Shares of the company have lost 1.2% in the past year against the industry’s 26.2% growth and the S&P 500's 39.6% rise.
Illumina’s long-term earnings growth rate is estimated at 7%.
DaVita’s long-term earnings growth rate is estimated at 14.4%.
Amedisys’ long-term earnings growth rate is estimated at 12%.
Zacks' Top Picks to Cash in on Artificial Intelligence
In 2021, this world-changing technology is projected to generate $327.5 billion in revenue. Now Shark Tank star and billionaire investor Mark Cuban says AI will create "the world's first trillionaires." Zacks' urgent special report reveals 3 AI picks investors need to know about today.
Image: Bigstock
BD (BDX) to Boost Lab Efficacy With BD Kiestra UCA's U.S. Launch
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, recently announced the U.S. launch of a Urine Culture Application (“UCA”) for use with the BD Kiestra lab automation incubation and imaging system. The application, which has been designed utilizing AI and leveraging the quality of BD BBL plated media, is expected to change the way microbiology labs approach urine culture analysis.
For investors’ note, the latest urine culture app can be used with both standalone BD Kiestra ReadA systems as well as track-based BD Kiestra laboratory automation solutions.
With the latest launch, BD aims to solidify its foothold in the global Integrated Diagnostic Solutions business. Notably, the Integrated Diagnostic Solutions is a part of the broader BD Life Sciences segment.
Significance of the Launch
It is noteworthy to mention that urine cultures consist of a significant part of the daily workload in many labs. However, the majority of those samples do not require any additional work-up.
The UCA is expected to utilize digital imaging and software algorithms to determine the amount of growth on a urine culture plate from clean-caught and catheterized samples. The BD Kiestra system's intelligent incubation and imaging device uses high-throughput robotics to decide which plates automatically go into a queue for clinician analysis and discards the rest.
Per management, the use of the UCA to automatically organize specimens into meaningful worklists is expected to help laboratories work more efficiently and better prioritize their efforts to focus on the most critical and complex specimens. Further, as reading plates is one of the laboratory tasks requiring the maximum skill, and given the dearth of skilled technicians in the workforce along with the pandemic-led challenges to the resources, lab efficiency is of utmost importance.
Industry Prospects
Per a report by Fior Markets, the global urinalysis market is expected to grow from $3.37 billion in 2019 to $6.32 billion by 2027 at a CAGR of approximately 8.1%. Factors like increasing cases of kidney-related diseases and rapid technological developments are likely to drive the market.
Given the market potential, the latest launch is expected to significantly strengthen BD’s global business.
Recent Developments
Of late, BD has witnessed a few notable developments across its businesses.
The company, this month, launched the BD Surgiphor Sterile Wound Irrigation System. It is the first and only ready-to-use aqueous povidone-iodine (PVP-I) irrigation solution currently available in the market which mechanically loosens and removes wound debris.
Also in May, BD announced that the industry's first self-collection claim for HPV screening has received the CE mark. The same month, the company reported solid fiscal 2021 second-quarter results with solid contribution by its COVID-19 diagnostic revenues.
In April, the company, along with CerTest Biotec, announced that the VIASURE SARS-CoV-2 (N1 + N2) Real Time PCR (polymerase chain reaction) Detection Kit for the BD MAX Molecular Diagnostic System can be run on saliva specimens.
Price Performance
Shares of the company have lost 1.2% in the past year against the industry’s 26.2% growth and the S&P 500's 39.6% rise.
Zacks Rank & Key Picks
Currently, BD carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Illumina, Inc. (ILMN - Free Report) , DaVita Inc. (DVA - Free Report) and Amedisys, Inc. (AMED - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Illumina’s long-term earnings growth rate is estimated at 7%.
DaVita’s long-term earnings growth rate is estimated at 14.4%.
Amedisys’ long-term earnings growth rate is estimated at 12%.
Zacks' Top Picks to Cash in on Artificial Intelligence
In 2021, this world-changing technology is projected to generate $327.5 billion in revenue. Now Shark Tank star and billionaire investor Mark Cuban says AI will create "the world's first trillionaires." Zacks' urgent special report reveals 3 AI picks investors need to know about today.
See 3 Artificial Intelligence Stocks With Extreme Upside Potential>>